A randomized phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.

被引：0
|
作者：
Kim, Hyung-Don
Yoo, Changhoon
Ryu, Min-Hee
Kang, Yoon-Koo
机构：
[1] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[2] Univ Uslan, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11538
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I study of two dosing schedules of BI 847325, an orally administered dual inhibitor of MEK and aurora kinase B, in patients with advanced solid tumors.
    Aftimos, Philippe
    Dumez, Herlinde
    Awada, Ahmad
    Billiet, Maureen
    Deleporte, Amelie
    De Block, Katrien
    Costermans, Jo
    Meeus, Marie-Anne
    Goeldner, Rainer-Georg
    Schnell, David
    Lee, Chooi
    Schoffski, Patrick
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [42] Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial
    Casali, P. G.
    Le Cesne, A.
    Poveda, A.
    Kotasek, D.
    Rutkowski, P.
    Hohenberger, P.
    Fumagalli, E.
    Judson, I.
    Italiano, A.
    Gelderblom, H.
    Penel, N.
    Kopp, H-G.
    Goldstein, D.
    Martin Broto, J.
    Gronchi, A.
    Wardelmann, E.
    Marreaud, S.
    Zalcberg, J.
    Litiere, S.
    Blay, J-Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors
    Beckermann, Kathryn E.
    Bestvina, Christine M.
    El Osta, Badi
    Sanborn, Rachel E.
    Borghaei, Hossein
    Lammers, Philip Edward
    Selvaggi, Giovanni
    Whisenant, Jennifer G.
    Heimann-Nichols, Ellen
    Berry, Lynne
    Hsu, Chih-Yuan
    Shyr, Yu
    Horn, Leora
    Wakelee, Heather
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (02):
  • [44] A phase I dose escalation study of BIBW 2992, an irreversible tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR-1) and 2 (HER 2) in a 2 week on 2 week off schedule in patients with advanced solid tumors.
    Eskens, FA
    Mom, CH
    Planting, AS
    Gietema, JA
    Aamelsberg, A
    Huisman, H
    Verweij, J
    de Vries, EG
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9023S - 9023S
  • [45] Imatinib Plus Low-Dose Doxorubicin in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to High-Dose Imatinib A Phase I-II Study by the Spanish Group for Research on Sarcomas
    Maurel, Joan
    Sofia Martins, Ana
    Poveda, Andres
    Antonio Lopez-Guerrero, Jose
    Cubedo, Ricardo
    Casado, Antonio
    Martinez-Trufero, Javier
    Ramon Ayuso, Juan
    Lopez-Pousa, Antonio
    Garcia-Albeniz, Xabier
    Garcia del Muro, Xavier
    de Alava, Enrique
    CANCER, 2010, 116 (15) : 3692 - 3701
  • [46] A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors.
    Donehower, R. C.
    Scardina, A.
    Hill, M.
    Bowman, J.
    Newton, R. C.
    Liu, X.
    Scherle, P.
    Wang, Q.
    Diamond, S.
    Boer, J.
    Lee, F.
    Gau, T.
    Burris, H. A.
    Bendell, J. C.
    Jones, S. F.
    Infante, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and I in a 4 week on, 2 week off schedule in patients with advanced solid tumors.
    Eskens, F. A.
    Planting, A.
    Van Doorn, L.
    Isoe, T.
    Hayashi, K.
    Hussain, S.
    Ekman, L.
    Burger, H.
    Verweij, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 87S - 87S
  • [48] Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs).
    George, Suzanne
    Demetri, George D.
    Lydon, Nick
    Kadambi, Vivek
    Christo, Jessica
    Johnson, Debbie
    Schoffski, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS483 - TPS483
  • [49] Phase I and pharmacological study of KRN951, a potent VEGFR tyrosine kinase inhibitor given in a 4 week on, 2 week off schedule in patients with advanced solid tumors
    Eskens, F. A. L. M.
    de Jonge, M. J. A.
    Van Doorn, L.
    Isoe, T.
    Hayashi, K.
    Hussain, S.
    Ekman, L.
    Burger, H.
    Verweij, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 16 - 16
  • [50] A phase I pharmacological and pharmacodynamic study of MK-1775, a Weel tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.
    Leijen, S.
    Schellens, J. H.
    Shapiro, G.
    Pavlick, A. C.
    Tibes, R.
    Demuth, T.
    Viscusi, J.
    Cheng, J. D.
    Xu, Y.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345